Psoriasis is a chronic inflammatory disease of uncertain aetiology that affects approximately 2 of the population. Histologically, skin plaques and inflamed synovial tissue demonstrate an abundance of T cells and increased vascularity. E. Only one antiTNF agent is licensed in the UK for the treatment of rheumatoid arthritis. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. The activation of Th2 cells contributes to the development of chronic graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. Upregulation of the expression of endothelial adhesion molecules (ICAM-1, VCAM-1, E-selectin) and chemokines (MCP-1, MIP-2, RANTES and MIP-1alpha).
Psoriasis is one of the most common immune-mediated chronic, inflammatory skin diseases characterized by hyperproliferative keratinocytes and infiltration of T cells, dendritic cells, macrophages and neutrophils. Finally, we will briefly summarize the recent progress on the T cell and its related cytokine-targeted therapy for psoriasis treatment. Psoriasis (Ps) and psoriatic arthritis (PsA) belong to the family of IMID, affecting predominantly the skin and joints. Chronic inflammatory systemic diseases could share common immune-mediated inflammatory pathways. Molecules and immune cells derived from both diseases may interact together in promoting a pathogenic effect. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and highly disabling diseases involving inappropriate or excessive immune responses caused or accompanied by cytokine dysregulation and acute or chronic inflammation 1. Aberrant proteins or peptide-MHC complexes on the surfaces of transformed or malignant cells are recognized and targeted for elimination by the immune system. Psoriasis is a chronic inflammatory skin disease characterized by circumscribed, erythemato-squamous plaques with adherent scales 72.
Official Full-Text Publication: IL-17 targeted therapies for psoriasis on ResearchGate, the professional network for scientists. Psoriasis is an immune-mediated skin disease appearing in a chronic recurring manner. Injectable biological therapies are emerging approaches for the treatment of psoriasis by targeting molecules in the inflammatory pathways. Psoriasis is a common relapsing and remitting immune-mediated inflammatory disease that affects the skin and joints. We highlight potential therapeutic targets and give an overview of the currently used immune-targeted therapies. (e) Typical chronic plaque psoriasis on extensor surfaces, namely the elbows.
Cellular & Molecular Immunology
Farley E, Masrour S, McKey J, Menter A. J Am Acad Dermatol. 2009 Jun;60(6):1024-31. In patients without risk factors for hepatic fibrosis, liver biopsies may not be indicated or the frequency of liver biopsies may be markedly reduced. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, Kalb RE,Hsu S. Psoriasis is a chronic inflammatory skin disease that affects approximately 23 of the Caucasian population. Psoriasis vulgaris is a chronic, debilitating skin disease that affects millions of people worldwide. This gene encodes an anti-inflammatory innate immune cytokine in the IL-1 family, and implicates the innate immune system in this systemic presentation of psoriasis. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Sorenson E, Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. These skin patches are typically red, itchy, and scaly. Psoriatic erythroderma (erythrodermic psoriasis) involves widespread inflammation and exfoliation of the skin over most of the body surface. Psoriasis in those with HIV/AIDS is often severe and may be untreatable with conventional therapy. Researchers have proposed differing descriptions of psoriasis and psoriatic arthritis; some authors have classified them as autoimmune diseases 15 31 57 while others have classified them as distinct from autoimmune diseases and referred to them as immune-mediated inflammatory diseases. (2008) The Safety and Efficacy of High-Dose Alefacept Compared With a Loading Dose of Alefacept in Patients With Chronic Plaque Psoriasis.
In the US, about 7.5 million people have psoriasis, a chronic immune-mediated, inflammatory disease. These drugs target very specific parts of the immune response, rather than affecting the entire immune system. Psoriasis is an immune-mediated inflammatory disease (IMID) affecting the skin which is associated with psoriatic arthritis in about one-third of patients (1212. The distinguishing feature of IMIDs is that their underlying pathology is caused by the dysfunction of the immune system, resulting in chronic and damaging inflammation. Hence, an effective treatment strategy for psoriasis should target this dysfunction and should take into account the genetic basis that persists despite clinically effective therapy. Psoriasis is an immune-mediated. Read more. 13, 2015 & 151; Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the. Read more. New target for psoriasis treatment discovered. Vitamin E Vitamin A Vitamin C Vitamin D Vitamin B. Current therapeutic agents are characterized by more specific targeting of defined molecules in the pathological pathways, including, most recently, the use of biologics, which target T cells (alefacept, efalizumab, and etanercept; approved by the US Food and Drug Administration FDA for the treatment of psoriasis), and TNF inhibitors (etanercept, infliximab, and adalimumab; approved by the FDA for the treatment of RA).